Cited by 175Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

Galluzzi, Lorenzo, Zitvogel, Laurence, Kroemer, Guido·2016·Cancer Immunology Research

Open this paper in CoChat — free account

Abstract

Accumulating preclinical and clinical evidence indicates that the success of several anticancer agents—including some conventional chemotherapeutics, targeted anticancer agents as well as specific forms of radiotherapy—depends (at least in part) on their ability to stimulate anticancer immune responses. Such immunostimulatory effects can be “on-target,” i.e., they originate within cancer cells, or “off-target,” i.e., they develop from a heretofore unsuspected interaction between cancer therapy and the immune system. Here, we briefly discuss the immunologic mechanisms that underlie the efficacy of some forms of cancer therapy, as we highlight the rationale for combining these treatment modalities with immunotherapy to achieve superior therapeutic effects. Cancer Immunol Res; 4(11); 895–902. ©2016 AACR.

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0197

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citation
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citation
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“For instance, loss-offunction alleles of P2RX7 (55), TLR4 (52, 56), FPR1 (51, 56), and Toll-like receptor 3 (TLR3, which is involved in type I IFN signaling; ref.”
BackgroundSelf-citation
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Show all 109 references

Sorted by citations

Items 101–175 of 175

Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review
Li, N., Xu, T., Zhou, Z., Li, P., Jia, G., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837547 · Cited by 8
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors
Qiao, M., Jiang, T., & Zhou, C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.99 · Cited by 7
Gas Plasma Technology and Immunogenic Cell Death: Implications for Chordoma Treatment
Bekeschus, S., Rössler, K., Kepp, O., & Freund, E. (2025) · Cancers · doi:10.3390/cancers17040681 · Cited by 7
Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells
Senjor, E., Ko, M.-W., Kaur, K., Chen, P.-C., Breznik, B., Chovatiya, N., Kos, J., & Jewett, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00020-3 · Cited by 7
Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs
Pörtner, R., Parida, S. K., Schaffer, C., & Hoffmeister, H. (2018) · InTech eBooks · doi:10.5772/intechopen.69335 · Cited by 7
Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation
Zhang, Q., Li, Y., Zhang, Y., Deng, Z., & Ding, Y. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03305-9 · Cited by 6
Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure
Li, M., Lin, C., Lin, J., Chen, S., Weng, L., & He, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14637 · Cited by 6
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin’s lymphoma: report on three cases and literature review
Romero, S., Balaguer‐Roselló, A., Montoro, J., Beneit, P., Martínez, A., Ruiz, C., Andreu, R., Guerreiro, M., Arnao, M., Montava, A., et al. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211038181 · Cited by 6
Bioinformatics Prediction and in vivo Verification Identify SLC7A5 as Immune Infiltration Related Biomarker in Breast Cancer
Zhu, Q., Wang, J., Shi, Y. E., Zha, X., & Wang, S. (2022) · Cancer Management and Research · doi:10.2147/cmar.s370397 · Cited by 7
Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysis
Liu, S., Li, X., Wu, C., Yao, L., Dong, H., Zhang, H., Wang, Y., Wang, M., & Xu, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002528 · Cited by 5
Epigenetic regulation of cancer
Galluzzi, L., & Spada, S. (2025) · International review of cytology · doi:10.1016/s1937-6448(25)00015-2 · Cited by 6
Self-citation
Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision
Zhang, X., Cui, H., Zhang, X., Zhang, Z., Liu, Z., Mao, R., Fan, Y., Sun, R., & Chen, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104908 · Cited by 7
First-line combination immunotherapy for metastatic non-small cell lung cancer
Chen, Y. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000287 · Cited by 5
Immunogenic Death of Hepatocellular Carcinoma Cells in Mice Expressing Caspase-Resistant ROCK1 Is Not Replicated by ROCK Inhibitors
Naylor, G. D., Julian, L., Watson-Bryce, S., Mullin, M., Nibbs, R. J. B., & Olson, M. F. (2022) · Cancers · doi:10.3390/cancers14235943 · Cited by 4
Inetetamab combined with pyrotinib and chemotherapy in the treatment of breast cancer brain metastasis: A case report
Dou, Q.-Q., Sun, T., Wang, G., & Tong, W.-B. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i3.575 · Cited by 4
Renewed interest for low‐dose radiation therapy in follicular lymphomas: From biology to clinical applications
Ciammella, P., Luminari, S., Arcaini, L., & Filippi, A. R. (2018) · Hematological Oncology · doi:10.1002/hon.2538 · Cited by 4
Hepatic artery infusion chemotherapy combined with lenvatinib and PD‑1 inhibitors in the treatment of intermediate and advanced unresectable hepatocellular carcinoma
Jiang, P., Li, F., Jiang, Z., Sun, Y., Yang, F., Chu, L.-S., Gai, Y., & Wang, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15183 · Cited by 3
Neoadjuvant chemoradiotherapy combined with immunotherapy: a promising strategy for MSS/pMMR locally advanced rectal cancer
Yang, L. F., Tang, J., Chi, Y., Li, H., Zhang, M., Zhang, H., Ma, X., Cheng, J., & Gao, C. (2025) · Medical Oncology · doi:10.1007/s12032-025-02918-8 · Cited by 3
Cancer Uses the Common Morphogenesis Source of the Host
Shoutko, A. N. (2020) · Open Journal of Biophysics · doi:10.4236/ojbiphy.2020.104013 · Cited by 3
Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
Lv, H., He, Y., Nie, C., Du, F., & Chen, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1067557 · Cited by 3
Initial interactions with the FDA on developing a validation dataset as a medical device development tool
Hart, S. N., Garcia, V. L., Dudgeon, S. N., Hanna, M. G., Li, X., Blenman, K., Elfer, K. N., Ly, A., Salgado, R., Saltz, J. H., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6208 · Cited by 3
The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019
Ascierto, P. A., Bifulco, C. B., Galon, J., Garbe, C., Khleif, S. N., McQuade, J. L., Odunsi, K. O., Okada, H., Paulos, C. M., Quezada, S. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000921 · Cited by 4
Supportive and Palliative Care in Cancer Therapies—Path from Tumor-Driven Therapies to Patient-Driven Ones
Minnaar, C. A., Szász, A., Lee, S. Y., Szigeti, G. P., Szász, A. M., & Máthé, D. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.137024 · Cited by 4
Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis
Zhao, Z., Yang, C., & Li, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03751-7 · Cited by 2
Immunotherapy combined with radiotherapy for advanced non‑small cell lung cancer: Current status and challenge (Review)
Li, Q., Cai, Y., Shao, L., Qi, Y., Guo, L., Song, H., Dong, Y., & Wei, S. (2025) · Oncology Letters · doi:10.3892/ol.2025.15215 · Cited by 3
Aryl hydrocarbon receptor-induced activation of AIM2 inflammasome is mediated by MOMP and MPT: A vital therapeutic pathway for inflammation
Chen, M., Liang, Z., Sun, M., Chen, Z., Peng, C., Khan, S., Abbas, M., Chen, D., & Xie, S. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116673 · Cited by 2
Cytofluorometric assessment of acute cell death responses driven by radiation therapy
Álvarez-Abril, B., Bloy, N., Galassi, C., Sato, A., Jiménez‐Cortegana, C., Klapp, V., Aretz, A., Guilbaud, E., Buqué, A., Galluzzi, L., et al. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.05.002 · Cited by 2
Self-citation
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2024) · International review of cytology · doi:10.1016/s1937-6448(24)00113-8 · Cited by 2
Self-citation
Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer
Gao, G., Jia, K., Zhao, S., Li, X., Zhao, C., Jiang, T., Su, C., Ren, S., Zhou, F., & Zhou, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.25 · Cited by 2
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19
Vitali, L., Merlini, A., Galvagno, F., Proment, A., & Sangiolo, D. (2022) · Biomedicines · doi:10.3390/biomedicines10102628 · Cited by 3
The First Year of HemaSphere and Many More to Come
Engert, A., & Cools, J. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000161 · Cited by 2
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(20)30020-3 · Cited by 2
Self-citation
Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities
Jia, H., Gong, Y., Zhao, C., Wei, H., & Zang, Q. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2635243 · Cited by 1
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2026) · International review of cytology · doi:10.1016/s1937-6448(26)00028-6 · Cited by 1
Self-citation
Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance
Niu, J., Jing, W., Liu, Z., Si, Y., & 刘寨东 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845547 · Cited by 1
Radiation therapy: An old dog learning new tricks
Sato, A., Kraynak, J., Marciscano, A. E. E., & Galluzzi, L. (2022) · Methods in cell biology · doi:10.1016/s0091-679x(22)00139-x · Cited by 1
Self-citation
Current and future developments of immunotherapy in lung cancer
Mauti, L. A., Finazzi, T., Früh, M., Pless, M., Zippelius, A., & Rothschild, S. I. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0411-3 · Cited by 1
Checkpoint inhibitors in head and neck cancer
Sepúlveda, I., Ascui, R. A., & Capizzano, A. A. (2019) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-019-0511-8 · Cited by 1
MKL1 is a key biomarker correlated with immune infiltrates and chemosensitivity in breast cancer
Hua, Y., & Yang, M. (2021) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.6306 · Cited by 1
Immunology and Immunotherapy of Ovarian Cancer
Wilczyński, J. R., Nowak, M., & Wilczyński, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_20 · Cited by 1
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(19)30459-8 · Cited by 1
Self-citation
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(20)30043-4 · Cited by 1
Self-citation
Tumor Immune Infiltrate and Response to Chemotherapy
Khamar, B. M. (2018) · Open Access Journal of Cancer & Oncology · doi:10.23880/oajco-16000127
Immunotherapy of renal cell carcinoma: Current state of the problem and promising areas of research
Molchanov, O. (2018) · Urology reports (St - Petersburg) · doi:10.17816/uroved8367-79
Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter
Rawluk, J. K., & Waller, C. F. (2018) · Pneumo News · doi:10.1007/s15033-018-0819-9
Engineering a CD19-Based Bispecific Molecule for CAR T Cell Therapy
Schrack, I. (2018) · University of Minnesota Digital Conservancy (University of Minnesota)
Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons
Buqué, A., & Galluzzi, L. (2021) · Methods in cell biology · doi:10.1016/s0091-679x(21)00040-6
Self-citation
Construction of smart assistive gloves for paralytic people
Ozsahin, D. U., Idoko, J. B., Jarwah, A., Badran, H., Wajid, N. A., & Özşahin, İ. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85413-9.00004-9
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(20)30077-x
Self-citation
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(20)30114-2
Self-citation
Immunological aspects of ovarian malignancy
Martins-Filho, A., Jammal, M. P., Murta, E. F. C., & Nomelini, R. S. (2022) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog4902035
Immunogenic cell death in mice expressing caspase-resistant ROCK1 is not replicated by ROCK inhibitorsPreprint
Naylor, G. D., Julian, L., Watson-Bryce, S., Mullin, M., Nibbs, R. J. B., & Olson, M. F. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.14.488346
Mechanisms of Resistance to Immunotherapies in Cancer
Lengyel, C. G. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_335-1
Radiation therapy: An old dog learning new tricks
Sato, A., Kraynak, J., Marciscano, A. E. E., & Galluzzi, L. (2023) · Methods in cell biology · doi:10.1016/s0091-679x(23)00036-5
Self-citation
Data from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2023) · doi:10.1158/1535-7163.c.6543510
Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2023) · doi:10.1158/1535-7163.22522875
Data from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
Miglietta, F., Ragazzi, M., Fernandes, B., Griguolo, G., Massa, D., Girardi, F., Bottosso, M., Bisagni, A., Zarrilli, G., Porra, F., et al. (2023) · doi:10.1158/1078-0432.c.6760515.v1
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2023) · International review of cytology · doi:10.1016/s1937-6448(23)00145-4
Self-citation
Radiation therapy: An old dog learning new tricks
Sato, A., Kraynak, J., Marciscano, A. E. E., & Galluzzi, L. (2023) · Methods in cell biology · doi:10.1016/s0091-679x(23)00166-8
Self-citation
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2024) · International review of cytology · doi:10.1016/s1937-6448(24)00026-1
Self-citation
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
Liu, K., Li, H., Tan, Q.-Q., Jiang, T., Peng, K., Chen, H.-J., Zhou, Q., Zhang, X., Zheng, Z., Chen, S., et al. (2025) · Science Progress · doi:10.1177/00368504251325406
Clinical Research Progress of Traditional Chinese Medicine Combined with PD-1 and PD-L1 Inhibitors in the Treatment of NSCLC
孙, 贵. (2025) · Traditional Chinese Medicine · doi:10.12677/tcm.2025.147459
Complete response to chemoimmunotherapy in a patient with metastatic squamous cell non-small cell lung cancer: A case report
Krivolapova, L. V., Meshcherin, V. O., Popov, S. O., & Алексеевна, А. Н. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-247
Mechanisms of Resistance to Immunotherapies in Cancer
Lengyel, C. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_335
Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors
Klein, M. A., Watson, D., Castro, M. P., Kapoor, S., Nair, P. R., Rajagopalan, S., Qin, H., Glaser, M., Westanmo, A. D., Lala, D. A., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.10.021
Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy
Niu, J., Zhu, H., Shi, Z., Sun, Z., Jing, X., & Zd, L. (2026) · Scientific Reports · doi:10.1038/s41598-026-54690-y
Additional file 2 of Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
Boustani, J., Joseph, E. L. M., Martin, E., Benhmida, S., Lecoester, B., Tochet, F., Mirjolet, C., Chevalier, C., Thibouw, D., Vulquin, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14811095
Additional file 3 of Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
Boustani, J., Joseph, E. L. M., Martin, E., Benhmida, S., Lecoester, B., Tochet, F., Mirjolet, C., Chevalier, C., Thibouw, D., Vulquin, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14811098
Additional file 1 of GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment
Raiter, A., Lipovettzky, J., Lubin, I., & Yerushalmi, R. (2020) · Figshare · doi:10.6084/m9.figshare.12154038
Additional file 1 of Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
Boustani, J., Joseph, E. L. M., Martin, E., Benhmida, S., Lecoester, B., Tochet, F., Mirjolet, C., Chevalier, C., Thibouw, D., Vulquin, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14811092
Invasive Urinary Bladder Cancer
Knapp, D. W., Hahn, N. M., Fulkerson, C. M., & Dhawan, D. (2026) · Springer eBooks · doi:10.1007/978-3-032-04454-9_11
Immunothérapie du cancer par administration d’anticorps monoclonaux anti-HVEM ou anti-ICOS chez la souris humanisée : potentiel thérapeutique et effets immunologiques
Brunel, S. (2017) · theses.fr (ABES) · doi:10.70675/c013f943z4c05z42b3z822ezecde2f929a63
The regulation of the p53 isoform p47 following Endoplasmic Reticulum (ER) stress, and physiological implication of single cancer-derived synonymous mutations in initiation of p53 mRNA translation
Fusée, L. T. S. (2020) · theses.fr (ABES) · doi:10.70675/7d11d779zac70z4ae9zba4bzd0c51b4ce40b
Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study
Liu, Y., Zhao, S., Du, F., Du, S., Song, L., Xia, T., Zhang, B., & Cui, B. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01401-5
Étude de la restauration de la réponse immunitaire antitumorale dans un modèle murin de cancer pulmonaire induit par une molécule multicible inhibitrice de HDAC et du splicéosome
Ducellier, S. (2023) · theses.fr (ABES) · doi:10.70675/cb4b0dd4z634bz4299z96a9z469b89375839

Authors: Galluzzi, L., Zitvogel, L., & Kroemer, G.
Affiliations: Inserm (FR)
Université Paris-Sud (FR)
Karolinska University Hospital (SE)
ORCID: Galluzzi, Lorenzo
Zitvogel, Laurence
Kroemer, Guido
Venue: Cancer Immunology Research
Publisher: American Association for Cancer Research (AACR)
Published: 2016-10-31
Volume: 4
Issue: 11
Pages: 895-902
ISSN: 2326-6066 (ISSN-L)
2326-6074
DOI: 10.1158/2326-6066.cir-16-0197
OpenAlex: W2547825706
Cited by: 175
References: 109
Citations by year: 2026: 6 · 2025: 14 · 2024: 13 · 2023: 16 · 2022: 22 · 2021: 24 · 2020: 25 · 2019: 10 · 2018: 29 · 2017: 13 · 2016: 1
FWCI: 1.78
Type: journal article
Language: en
Open access: closed
Locations: Cancer Immunology Research (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Ligue Contre le Cancer
Institut National Du Cancer
Institute of Cancer Research
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, antitumor immunity, chemotherapeutics, targeted anticancer agents, radiotherapy, combination therapy, tumor immunology
MeSH terms: Animals, Antigens, Neoplasm, Combined Modality Therapy, Disease Susceptibility, Humans, Immune System, Neoplasms, Treatment Outcome, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks